• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iRhythm Technologies Inc. (Amendment)

    1/27/23 4:29:23 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email
    SC 13G/A 1 irhythm.txt ANNUAL 13G IRHYTHM TECHNOLOGIES INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. Two)* iRhythm Technologies Inc (Name of Issuer) Common Shares (Title of Class of Securities) 450056106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. CUSIP No. 450056106 Schedule 13G Page 2 of 5 1. Name of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Mackenzie Financial Corporation 2. Check the Appropriate Box if a Member of a Group (a) [ ] (b) [x] 3. SEC Use Only 4. Citizenship or Place of Organization Toronto, Ontario, Canada Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 1,246,524 shares 6. Shared Voting Power NIL 7. Sole Dispositive Power 1,246,524 shares 8. Shared Dispositive Power NIL 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,246,524 shares 10. Check if the Aggregate Amount in Row (11) Excludes Certain Shares N/A 11. Percent of Class Represented by Amount in Row (9) 4.14% 12. Type of Reporting Person (See Instructions) IA Item 1. Schedule 13G Page 3 of 5 (a) Name of Issuer iRhythm Technologies Inc (b) Address of Issuer's Principal Executive Offices 650 Townsend Street, Suite 500 San Francisco, CA 94103 United States (a) Name of Person Filing Mackenzie Financial Corporation (b) Address of Principal Business Office or, if none, Residence 180 Queen Street West, Toronto, Ontario M5V 3K1 (c) Citizenship Organized in Toronto, Ontario, Canada (d) Title of Class of Securities Common Shares (e) CUSIP Number 450056106 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b), or (c) check whether the person filing is a(n): (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C.78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C.78c). (d) [ ] Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [X] investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) [ ] employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [ ] parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) [ ] savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); Schedule 13G Page 4 of 5 (i) [ ] church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J). Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1,246,524 (b) Percent of Class: 4.14% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote - 1,246,524 (ii) Shared power to vote or to direct the vote - NIL (iii) Sole power to dispose or to direct the disposition of - 1,246,524 (iv) Shared power to dispose or to direct the disposition of - NIL Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. Item 6. Ownership of More than Five Percent on Behalf of Another Person N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company N/A Item 8. Identification and Classification of Members of the Group N/A Item 9. Notice of Dissolution of Group N/A Schedule 13G Page 5 of 5 Item 10. Certification (a) The following certification shall be included if the statement is filed pursuant to 240.13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. (b) The following certification shall be included if the statement is filed pursuant to 240.13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date January 27, 2023 "Gillian Seidler" Signature Gillian Seidler Vice-President & Chief Compliance Officer Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
    Get the next $IRTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    9/23/2025$185.00In-line
    Evercore ISI
    8/20/2025$200.00Buy
    BofA Securities
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    More analyst ratings

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by iRhythm Technologies Inc.

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/3/25 4:35:58 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    CBO and CLO Murphy Patrick Michael sold $458,009 worth of shares (2,478 units at $184.83), decreasing direct ownership by 4% to 53,281 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/3/25 4:35:40 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang was granted 250 shares, increasing direct ownership by 0.60% to 41,643 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/2/25 6:34:35 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/5/24 5:35:18 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

    4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/6/23 7:08:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is

    2/5/26 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter 2025For full year 2026, expect revenue of approximately $870 million to $880 million, or approximat

    1/12/26 7:30:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference. iRhythm's management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events and Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digi

    12/29/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded iRhythm from In-line to Outperform and set a new price target of $210.00

    1/5/26 8:34:48 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on iRhythm with a new price target

    BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00

    8/20/25 8:56:18 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    SEC Filings

    View All

    SEC Form 15-12G filed by iRhythm Holdings Inc.

    15-12G - iRhythm Holdings, Inc. (0001388658) (Filer)

    1/30/26 4:07:27 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by iRhythm Technologies Inc.

    S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)

    1/12/26 5:03:48 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by iRhythm Technologies Inc.

    S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)

    1/12/26 5:02:05 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

    SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

    6/6/23 9:00:39 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Financials

    Live finance-specific insights

    View All

    iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is

    2/5/26 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Third Quarter 2025 Financial Results

    SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights

    10/30/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Report Third Quarter 2025 Financial Results on October 30, 2025

    SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadin

    10/16/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/7/24 4:05:49 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care